Introduction
============

Cerebrospinal fluid (CSF) levels of proteins and peptides associated with neuritic plaques and neurofibrillary tangles can enhance the accurate etiologic diagnosis of Alzheimer's disease (AD) ([@B26]; [@B16], [@B15]). These markers --beta-amyloid peptides (Aβ38, Aβ40, Aβ42), ([@B1]; [@B22]; [@B11]) total and phosphorylated tau ([@B2]; [@B10]; [@B8]) -- are measured in research and commercial laboratories around the world, but there remain key obstacles in their broader application. These include the need to purchase a research-based assay platform, pre-analytical and analytical variability, ([@B9]; [@B19]) and the need for experienced operators. While international quality control programs ([@B27]; [@B17]; [@B24]) aim to optimize measurement variability across assays, reagents, platforms, standards, operators, and algorithms, technological solutions including process engineering and assay automation can potentially reduce variability introduced by human operators that influence assay performance.

Immunoassays targeting Aβ42, t-Tau, and p-Tau~181~ have predominated the landscape of CSF AD biomarker analysis to date, although mass spectrometry-based assays are under development ([@B24]). Compared to solid-phase enzyme linked immunosorbent assays (ELISA) and fluid-phase Luminex assays which require manual reagent addition and removal on multi-well plates, automated analyzers are proposed to have better repeatability (variability within the same assay) and intermediate precision (variability between different assays). The Fujirebio Lumipulse^®^ system and the Roche Elecsys^®^ have shown consistent inter-assay measures in the serum, with coefficient of variation (CV) in the range of 1.2--10% for hepatitis B antigens, ([@B29]) tumor markers, ([@B21]) cortisol, ([@B28]) and interleukin-13 ([@B23]). In the CSF, a recent multi-center study using synthetic Aβ42 peptides in artificial CSF reported inter-assay CV of \<5% on the Elecys^®^ system, ([@B4]) but the intermediate precision of endogenous Aβ42 in human-derived CSF samples in these automated analyzers remains unknown. Because most cohort, ([@B7]; [@B26]; [@B3]) clinicopathologic, ([@B25]; [@B12]; [@B20]) and pharmacological ([@B5]; [@B18]) studies to-date have relied on one of the non-automated assays, it is also important to determine the measurement correlation between the three assay formats. Here we selected 30 human CSF samples representing a range of physiologic Aβ42 levels, characterized the correlation between CSF Aβ42 measurements from different assay types, and assessed the repeatability and intermediate precision of each assay.

Materials and Methods {#s1}
=====================

Standard Protocol Approvals and Patient Consents
------------------------------------------------

This study was carried out in accordance to US Code of Federal Regulations Title 45 Part 46 Protection of Human Subjects, and Emory University and Emory School of Medicine policies. The protocols were approved by the Emory University Institutional Review Board. Banked CSF samples were used for this study, and all subjects had previously given written informed consent according to the Declaration of Helsinki for long-term sample storage and future analysis.

CSF Pooling and Aliquotting
---------------------------

Cerebrospinal fluid samples were all previously collected using a modified AD Neuroimaging Initiative protocol ([@B13]). Briefly, CSF was collected into 15 mL polypropylene tubes via a 24-gauge atraumatic needle and syringe aspiration without overnight fasting. Polypropylene tubes were inverted several times, and CSF was aliquotted (500 μL), labeled, and frozen at -80°C until analysis.

Cerebrospinal fluid samples from 30 subjects were selected for the study (**Table [1](#T1){ref-type="table"}**). Subjects were chosen to represent a wide range of Aβ42 concentrations (previously measured using Luminex): nine had normal cognition, 12 had mild cognitive impairment, six had AD dementia, and three had other non-AD dementias (one each for corticobasal syndrome, dementia with Lewy bodies, and progressive supranuclear palsy).

###### 

Characteristics of subjects and assays according to CSF Aβ42 concentrations.

                                            Low(*n* = 10)   Intermediate(*n* = 10)   High(*n* = 10)
  ----------------------------------------- --------------- ------------------------ ----------------
  Female (%)                                3 (30%)         7 (70%)                  3 (30%)
  Age, yr *(SD)*                            72.7 (7.9)      65.5 (8.5)               72.5 (8.4)
  Diagnosis                                                                          
    Normal cognition                        3               2                        4
    Mild cognitive impairment               4               2                        6
    AD dementia                             2               4                        0
    Other dementia                          1               2                        0
  Aβ42~CLEIA~, pg/mL *(SD)*                 219.5 (50.2)    327.7 (51.0)             821.5 (194.4)
  Aβ42~Luminex~, pg/mL *(SD)*               105.7 (29.3)    173.3 (42.4)             400.9 (68.6)
  Aβ42~ELISA,~ pg/mL *(SD)*                 265.9 (56.6)    363.3 (66.1)             698.0 (97.6)
  t-Tau~Luminex~, pg/mL *(SD)*              51.2 (50.9)     64.3 (62.1)              33.5 (7.8)
  p-Tau~Luminex~, pg/mL *(SD)*              22.9 (24.7)     42.2 (48.8)              7.1 (6.9)
  Intra-assay CV (repeatability)                                                     
    CLEIA                                   2.4%            2.1%                     1.4%
    Luminex                                 12.0%           13.3%                    9.4%
    ELISA                                   3.3%            3.6%                     3.1%
  Inter-assay CV (intermediate precision)                                            
    CLEIA                                   10.1%           7.1%                     4.0%
    Luminex                                 11.8%           11.5%                    8.8%
    ELISA                                   14.6%           9.8%                     7.8%

Because we wished to compare the platforms' performance over three weekly runs, we first generated identical CSF aliquots for all runs (**Figure [1](#F1){ref-type="fig"}**). For each subjects, four 500 μL CSF aliquots were thawed at room temperature, vortexed, and pooled into a 5 mL polypropylene tube. The pooled 2 mL aliquot was then vortexed and separated into three 250 μL aliquots and three 370 μL aliquots. All aliquots were then re-frozen to ensure the same freeze-thaw cycles in addition to the same number of tube transfers.

![Assessment of correlation between CSF Aβ42 levels measured in CLEIA, Luminex, and ELISA across three weekly runs. For each subject, four frozen 500 μL aliquots were thawed, pooled, and realiquoted. On the first day of each week, aliquots were thawed for analysis on the three platforms. In the correlational figures, CLEIA measures are presented on the *X*-axis, and the ELISA and Luminex measures are presented on the *Y*-axis.](fnagi-10-00253-g001){#F1}

CSF Analysis
------------

On the first day of each study week, every sample was analyzed in triplicates (three wells) on the automated Lumipulse^®^ Aβ42 chemiluminescent enzyme immunoassay (CLEIA), INNO-Bia Alzbio3 Luminex assay, and INNOTEST^®^ Aβ42 ELISA. In the morning, one 370 μL aliquot was thawed at room temperature for each subject and analyzed using the ELISA according to the manufacturer's protocol on two separate 96-well plates. A full set of kit standards and two kit controls were included in each plate. The inter-plate CV for the kit controls were 4.7 and 18.0% on Week 1, 2.9, and 4.8% on Week 2, and 21.6 and 13.4% on Week 3. The remaining CSF from each 370 μL aliquot was transferred to the CLEIA sample cups for Aβ42 analysis following the manufacturer's protocol.

In the afternoon, one 250 μL aliquot was thawed at room temperature for Luminex assays according to a modified manufacturer's protocol: all samples were vortexed vigorously for exactly 15 s immediately prior to plate loading, ([@B14]) and the bead count (performed the next day) was reduced to 75 to minimize fluorescence loss. As with the ELISA, samples were divided between two plates, with a full set of kit standards and two kit controls on each plate. The inter-plate CVs for the two kit controls were 0.2 and 0.9% on Week 1, 6.1 and 2.8% on Week 2, and 4.7 and 1.9% on Week 3.

Statistical Analysis
--------------------

Statistical analyses were performed using IBM SPSS version 24.0 (Armonk, NY, United States). Aβ42 concentrations measured by CLEIA, Luminex, and ELISA were all log-transformed prior to Pearson's correlation analysis due to their non-normal distribution, with *p* \< 0.01 to account for multiple comparisons. Repeatability for each assay was assessed by averaging CV for the triplicate concentration values within the same run, and intermediate precision for each assay was assessed by calculating CV for the three weekly concentrations. Analysis of variance (ANOVA) and analysis of co-variance (ANCOVA) were used to determine whether intermediate precision differed between the three assays before and after adjusting for Log~10~-transformed concentrations.

Data Availability
-----------------

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Results
=======

Aβ42 Levels Were Highly Correlated Between the Three Assays
-----------------------------------------------------------

There was a very high degree of correlation between concentrations from all three platforms (*R* = 0.964--0.973 between CLEIA and Luminex, 0.961--0.967 between CLEIA and ELISA, and 0.932--0.969 between Luminex and ELISA). Regression analysis showed that a quadratic -- rather than linear -- relationship better converted measures from ELISA and Luminex to CLEIA due to relatively higher CLEIA measures than ELISA/Luminex measures in the high concentration range \[**Figure [1](#F1){ref-type="fig"}**, Aβ42~CLEIA~ = 63.32 + 0.32Aβ42~ELISA~ + 0.001Aβ42~ELISA^2^~, Aβ42~CLEIA~ = 100 + 0.92Aβ42~Luminex~ + 0.002Aβ42~Luminex^2^~\]. In contrast, the relationship between Luminex and ELISA was linear in all concentrations (Aβ42~Luminex~ = 0.66Aβ42~ELISA~ -66.35).

Repeatability
-------------

The average intra-assay CV for Aβ42~CLEIA~ was \<2.5% for all Aβ42 levels (**Table [1](#T1){ref-type="table"}**). These were comparable to values for Aβ42~ELISA~, but lower than values for Aβ42~Luminex~ as expected from the reduced bead count per well. Among 90 triplicates, two samples (2%, from the same subject) on CLEIA and five samples from ELISA had intra-assay CV greater than 5%.

Intermediate Precision
----------------------

The average inter-assay (within laboratory) CV for Aβ42~CLEIA~ ranged from 4.0% for high concentrations to 10.1% for low concentrations (**Table [1](#T1){ref-type="table"}**). When all concentrations were analyzed together, ANOVA showed that Aβ42~CLEIA~ (7.1%) had lower inter-assay CV than the other platforms \[**Figure [2A](#F2){ref-type="fig"}**, 10.7% for Aβ42~Luminex~ (*p* = 0.0090), 10.8% for Aβ42~ELISA~ (*p* = 0.009)\]. ANCOVA adjusting for Aβ42~CLEIA~ concentrations (**Figure [2B](#F2){ref-type="fig"}**) showed that, in addition to an inverse relationship between CV and concentration (*p* \< 0.001), CLEIA had greater intermediate precision than Luminex at higher concentrations (*p* = 0.001 for assay X concentration), and greater intermediate precision over ELISA at all concentrations (*p* \< 0.001 for assay).

![Intermediate precision of CLEIA-, Luminex-, and ELISA-based CSF Aβ42 measures. Across all concentrations, Aβ42~CLEIA~ measures had lower CV than Aβ42~Luminex~ or Aβ42~ELISA~ **(A)**. Further examination of the differences in CV **(B)** showed that Aβ42~CLEIA~ had lower inter-assay CV than Aβ42~Luminex~ at higher concentrations (^∗^), and Aβ42~ELISA~ at all concentrations (^∗∗^).](fnagi-10-00253-g002){#F2}

Discussion
==========

While CSF biomarkers have shown great promise in the ante-mortem prediction of AD pathology, pre-analytical and analytical processes need to be standardized and simplified for inclusion into existing clinical workflows. Because every step -- pre-analytical or analytical -- affords an opportunity for within-operator and between-operator variability, automation of the analytical portion of Aβ42 measurements likely reduced the within-operator, inter-assay imprecision ([@B4]; [@B6]). Operator-associated imprecision in the busy clinical laboratories is likely much greater, as published inter-assay CV values generally come from experienced biomarker laboratories (5.3--14% for Luminex and 6.4--25% for ELISA) with experienced staff dedicated to these specialized assays ([@B17]). At the same time, inconsistent reporting of intermediate precision -- particularly related to source material \[e.g., synthetic peptides, ([@B4]) pooled CSF ([@B6])\] -- prevents comparison across manual and automated platforms, as well as across different automated platforms. While the study design here required a modest amount of CSF from each subject, involving banked samples from multiple centers or recruiting study volunteers specifically for the purpose of assay standardization can streamline future studies for new assays or analyzers.

The strong correlation between Aβ42~CLEIA~ and the other Aβ42 measures also permits comparison between legacy and new data. The correlation observed here is stronger than that reported between another automated analyzer and the same ELISA we used ([@B6]). The difference likely resulted from our use of CLEIA and ELISA from the same manufacturer. Our observation of non-linear relationship in higher Aβ42 concentrations also warrants follow-up, as this observation was not specifically examined with the other analyzers. Nevertheless, we report good repeatability, intermediate precision, and strong correlation with established Aβ42 assays. Because the automated analyzer already has FDA clearance in the United States, CSF Aβ42 measurement will likely not be limited to specialized centers in the near future. At the same time, because CSF collection and handling are still manual in nature, there is an ever more urgent need to standardize these pre-analytical steps through processing engineering and possibly automation.
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